Diagnosis and classification of myelodysplastic syndromes |
Dec 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
Jul 2020 |
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study |
May 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Guideline-based indicators for adult patients with myelodysplastic syndromes |
Aug 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
Jul 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |